Olema Pharmaceuticals Inc
OLMA8.510USD
+0.760+9.81%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
584.02MMarket Cap
LossP/E TTM
More Details of Olema Pharmaceuticals Inc Company
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Company Info
Ticker SymbolOLMA
Company nameOlema Pharmaceuticals Inc
IPO dateNov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
Number of employees96
Security typeOrdinary Share
Fiscal year-endNov 19
Address780 Brannan Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94103
Phone14156513316
Websitehttps://olema.com/
Ticker SymbolOLMA
IPO dateNov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ian Clark
Mr. Ian Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sean P. Bohen, M.D., Ph.D.
Mr. Sean P. Bohen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Shane Kovacs
Mr. Shane Kovacs
Chief Operating and Financial Officer
Chief Operating and Financial Officer
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
9.97%
Paradigm BioCapital Advisors LP
9.86%
BVF Partners L.P.
7.72%
BlackRock Institutional Trust Company, N.A.
5.77%
Woodline Partners LP
5.11%
Other
61.58%
Shareholders
Shareholders
Proportion
Bain Capital Life Sciences Investors, LLC
9.97%
Paradigm BioCapital Advisors LP
9.86%
BVF Partners L.P.
7.72%
BlackRock Institutional Trust Company, N.A.
5.77%
Woodline Partners LP
5.11%
Other
61.58%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.44%
Investment Advisor
29.79%
Investment Advisor/Hedge Fund
27.27%
Venture Capital
9.80%
Research Firm
4.23%
Individual Investor
4.16%
Pension Fund
0.11%
Bank and Trust
0.11%
Insurance Company
0.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
320
70.59M
103.16%
-12.18M
2025Q1
327
72.74M
106.44%
-11.08M
2024Q4
313
78.82M
113.63%
+3.60M
2024Q3
301
63.64M
110.87%
-10.05M
2024Q2
299
62.60M
111.72%
-7.29M
2024Q1
288
60.06M
107.83%
-1.82M
2023Q4
271
55.06M
100.31%
-2.15M
2023Q3
263
50.27M
92.75%
-945.85K
2023Q2
259
39.52M
96.98%
-9.43M
2023Q1
256
36.49M
89.86%
-12.60M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bain Capital Life Sciences Investors, LLC
6.84M
10%
+2.44M
+55.54%
Mar 31, 2025
Paradigm BioCapital Advisors LP
6.74M
9.85%
-563.80K
-7.72%
Mar 31, 2025
BVF Partners L.P.
5.30M
7.74%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.32M
4.85%
+40.22K
+1.23%
Mar 31, 2025
Woodline Partners LP
1.48M
2.16%
+120.43K
+8.87%
Mar 31, 2025
Deep Track Capital LP
3.44M
5.03%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.87M
4.2%
+193.65K
+7.23%
Mar 31, 2025
Logos Global Management LP
3.21M
4.69%
--
--
Apr 21, 2025
Franklin Advisers, Inc.
3.01M
4.4%
+2.74M
+1000.44%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
